Robinson Health System, INC.
Robinson Health System, INC. was paid $26.26M by Medicaid between Jan 2018 and Dec 2024, across 356 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
RAVENNA, OH 44266
Next to other General Acute Care Hospital providers in Ohio
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 68,929 | $2.39M | |
| 2019 | 57,892 | $2.15M | |
| 2020 | 47,612 | $2.36M | |
| 2021 | 66,166 | $2.93M | |
| 2022 | 63,759 | $2.83M | |
| 2023 | 209,813 | $8.20M | |
| 2024incomplete | 153,686 | $5.42M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 37,859 | 34,946 | $4.53M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 23,301 | 20,610 | $3.07M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.0% | 7,790 | 6,302 | $2.09M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.0% | 15,750 | 13,605 | $1.83M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.4% | 13,318 | 12,437 | $1.67M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.2% | 13,858 | 13,118 | $1.62M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 3,585 | 2,914 | $849K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 3,430 | 2,729 | $764K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.9% | 10,990 | 3,462 | $759K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.5% | 3,972 | 1,931 | $402K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 2,737 | 1,840 | $389K |
| 80053 | Comprehensive metabolic panel | 1.3% | 31,949 | 27,063 | $354K |
344 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 1,102 | $297K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 1,139 | $289K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.0% | 1,516 | $273K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 10,195 | $268K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 1,299 | $267K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.0% | 718 | $264K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,217 | $260K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 925 | $236K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,048 | $226K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,012 | $218K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,270 | $216K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 433 | $189K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,967 | $177K |
| 86481 | <1% | 2,607 | $170K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,254 | $159K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,256 | $137K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,220 | $114K |
| 86780 | <1% | 2,939 | $113K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 822 | $109K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,796 | $102K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 792 | $99K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 903 | $98K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 42,812 | $92K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,096 | $91K |
| 80355 | <1% | 4,869 | $86K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,126 | $85K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 967 | $84K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,901 | $82K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 237 | $77K |
| G0378 | Hospital observation service, per hour | <1% | 1,597 | $76K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 104 | $74K |
| 36415 | Collection of venous blood by venipuncture | <1% | 31,779 | $74K |
| 82077 | <1% | 4,333 | $70K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,539 | $69K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 241 | $63K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,076 | $61K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,154 | $58K |
| 97161 | <1% | 1,259 | $51K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,225 | $51K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 88 | $50K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,858 | $47K |
| 80074 | <1% | 2,706 | $47K | |
| 76642 | <1% | 544 | $47K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,766 | $46K |
| 85027 | <1% | 6,694 | $46K | |
| 93017 | <1% | 607 | $45K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,158 | $45K |
| 80061 | Lipid panel | <1% | 3,493 | $44K |
| 93971 | <1% | 616 | $42K | |
| 71250 | <1% | 496 | $42K | |
| 73630 | <1% | 1,355 | $41K | |
| 82805 | <1% | 1,714 | $41K | |
| 87522 | Neg quan hep c or qual rna | <1% | 674 | $40K |
| 97113 | <1% | 692 | $40K | |
| 73030 | <1% | 1,125 | $39K | |
| 76770 | <1% | 256 | $38K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 86 | $38K |
| 71271 | <1% | 265 | $37K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 381 | $37K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,574 | $37K |
| 76536 | <1% | 340 | $36K | |
| 88142 | <1% | 1,937 | $36K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 283 | $33K |
| 11045 | <1% | 73 | $33K | |
| 87205 | <1% | 2,023 | $33K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,920 | $30K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 914 | $30K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,161 | $30K |
| 73562 | <1% | 614 | $29K | |
| 12001 | <1% | 189 | $28K | |
| 94060 | <1% | 261 | $26K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,721 | $26K |
| 73564 | <1% | 956 | $25K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,431 | $25K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 507 | $24K |
| 86140 | <1% | 1,339 | $24K | |
| 80354 | <1% | 1,771 | $24K | |
| 73130 | <1% | 991 | $24K | |
| 73610 | <1% | 981 | $22K | |
| 84484 | <1% | 10,197 | $22K | |
| 93458 | <1% | 20 | $22K | |
| 82607 | <1% | 776 | $22K | |
| 97162 | <1% | 488 | $22K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 725 | $20K |
| 73110 | <1% | 761 | $20K | |
| 84439 | <1% | 829 | $20K | |
| 80349 | <1% | 806 | $19K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,538 | $19K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 29 | $19K |
| 97165 | <1% | 388 | $18K | |
| 70491 | <1% | 71 | $18K | |
| 73502 | <1% | 598 | $18K | |
| 86850 | <1% | 1,040 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 999 | $17K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,419 | $16K |
| 72100 | <1% | 419 | $15K | |
| 80353 | <1% | 1,001 | $15K | |
| 70486 | <1% | 391 | $15K | |
| 93975 | <1% | 95 | $15K | |
| 72114 | <1% | 216 | $14K | |
| 94726 | <1% | 273 | $14K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 113 | $14K |
| 74018 | <1% | 430 | $14K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,718 | $13K |
| 80361 | <1% | 1,083 | $13K | |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | <1% | 1,431 | $13K |
| 80346 | <1% | 959 | $12K | |
| 74183 | <1% | 49 | $12K | |
| 96367 | <1% | 300 | $12K | |
| 80320 | <1% | 838 | $12K | |
| 73560 | <1% | 319 | $12K | |
| 83605 | <1% | 7,201 | $12K | |
| 82728 | <1% | 539 | $11K | |
| 93296 | <1% | 676 | $11K | |
| 94729 | <1% | 246 | $11K | |
| 76982 | <1% | 237 | $10K | |
| 72170 | <1% | 311 | $9K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,549 | $9K |
| 86900 | <1% | 1,043 | $9K | |
| 83735 | <1% | 4,856 | $8K | |
| 80324 | <1% | 553 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,809 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,104 | $8K |
| 11043 | <1% | 55 | $8K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 240 | $7K |
| 80348 | <1% | 1,183 | $7K | |
| 90715 | <1% | 487 | $7K | |
| 70496 | <1% | 19 | $7K | |
| 80365 | <1% | 1,095 | $7K | |
| 81001 | <1% | 14,342 | $7K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 29 | $7K |
| 87634 | <1% | 353 | $6K | |
| 93970 | <1% | 49 | $6K | |
| 72131 | <1% | 128 | $6K | |
| 96376 | <1% | 1,951 | $6K | |
| 83540 | <1% | 531 | $6K | |
| 82947 | <1% | 4,606 | $6K | |
| 76801 | <1% | 52 | $6K | |
| 77062 | <1% | 155 | $5K | |
| 99152 | <1% | 424 | $5K | |
| 82570 | <1% | 466 | $5K | |
| 83992 | <1% | 256 | $4K | |
| 72110 | <1% | 83 | $4K | |
| 87070 | <1% | 561 | $4K | |
| 87505 | <1% | 25 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 28 | $4K |
| 85610 | <1% | 2,931 | $4K | |
| 80358 | <1% | 671 | $4K | |
| 76981 | <1% | 35 | $4K | |
| 97116 | <1% | 321 | $4K | |
| 80373 | <1% | 646 | $4K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 16 | $4K |
| 73080 | <1% | 189 | $4K | |
| J3490 | Unclassified drugs | <1% | 2,929 | $3K |
| 80368 | <1% | 632 | $3K | |
| 73590 | <1% | 285 | $3K | |
| 80372 | <1% | 609 | $3K | |
| 80076 | <1% | 719 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 158 | $3K |
| 81003 | <1% | 4,622 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 79 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 14 | $3K |
| 80331 | <1% | 256 | $3K | |
| 80334 | <1% | 256 | $3K | |
| 80337 | <1% | 256 | $3K | |
| 80338 | <1% | 256 | $3K | |
| 83880 | <1% | 1,888 | $3K | |
| 80326 | <1% | 256 | $3K | |
| 84702 | <1% | 1,355 | $3K | |
| 80366 | <1% | 256 | $3K | |
| 80344 | <1% | 256 | $3K | |
| 80341 | <1% | 256 | $3K | |
| 80370 | <1% | 256 | $3K | |
| 80377 | <1% | 256 | $3K | |
| 80367 | <1% | 256 | $3K | |
| 80357 | <1% | 256 | $3K | |
| 70498 | <1% | 37 | $3K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 14 | $3K |
| 12002 | <1% | 17 | $3K | |
| 80360 | <1% | 256 | $3K | |
| 80359 | <1% | 256 | $3K | |
| 80364 | <1% | 256 | $3K | |
| 80371 | <1% | 256 | $3K | |
| 83690 | <1% | 4,842 | $3K | |
| 81025 | <1% | 6,282 | $3K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 44 | $2K |
| 97035 | <1% | 26 | $2K | |
| 93922 | <1% | 27 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 511 | $2K |
| 80345 | <1% | 93 | $2K | |
| 99201 | <1% | 47 | $2K | |
| 82043 | <1% | 336 | $2K | |
| 84100 | <1% | 794 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 26 | $2K |
| 80069 | <1% | 204 | $2K | |
| 87077 | <1% | 512 | $2K | |
| 73140 | <1% | 99 | $2K | |
| 72040 | <1% | 59 | $2K | |
| 87186 | <1% | 875 | $2K | |
| 80143 | <1% | 1,463 | $2K | |
| 82248 | <1% | 695 | $2K | |
| 86318 | <1% | 39 | $1K | |
| 12011 | <1% | 15 | $1K | |
| 86703 | <1% | 84 | $1K | |
| 77080 | <1% | 24 | $1K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 475 | $1K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 23 | $1K |
| 83550 | <1% | 115 | $1K | |
| 72052 | <1% | 13 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 187 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,770 | $1K |
| 84466 | <1% | 106 | $1K | |
| 86901 | <1% | 1,044 | $1K | |
| 87800 | <1% | 223 | $1K | |
| 71101 | <1% | 43 | $1K | |
| 82330 | <1% | 1,290 | $1K | |
| 00731 | <1% | 382 | $1K | |
| 87040 | <1% | 1,420 | $981.87 | |
| 93246 | <1% | 14 | $970.55 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,684 | $961.61 |
| 72070 | <1% | 13 | $883.74 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,212 | $878.31 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 34 | $870.13 |
| 73090 | <1% | 97 | $854.56 | |
| 82565 | <1% | 105 | $842.04 | |
| 80179 | <1% | 1,443 | $826.46 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 121 | $811.84 |
| 87653 | <1% | 27 | $752.34 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,930 | $746.40 |
| 94618 | <1% | 15 | $723.40 | |
| 87210 | <1% | 291 | $710.25 | |
| 77061 | <1% | 12 | $684.57 | |
| 85018 | <1% | 1,340 | $664.32 | |
| 87075 | <1% | 1,127 | $658.65 | |
| 87799 | <1% | 22 | $645.81 | |
| 82550 | <1% | 512 | $622.63 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 90 | $621.61 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 71 | $601.05 |
| 84132 | <1% | 1,328 | $590.26 | |
| 87493 | <1% | 23 | $564.32 | |
| 87340 | <1% | 47 | $563.59 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,019 | $559.20 |
| 82435 | <1% | 1,219 | $532.07 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,852 | $516.66 |
| 85652 | <1% | 497 | $511.95 | |
| 87081 | <1% | 29 | $456.22 | |
| 85730 | <1% | 735 | $419.36 | |
| 82542 | <1% | 40 | $411.67 | |
| 85379 | <1% | 902 | $404.92 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13 | $384.06 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 354 | $379.62 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 666 | $359.64 |
| 00812 | <1% | 48 | $350.73 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,220 | $321.89 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,365 | $319.33 |
| 84295 | <1% | 1,223 | $316.70 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 67 | $298.47 |
| 80055 | <1% | 12 | $268.81 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 15 | $257.97 |
| 87280 | <1% | 12 | $248.16 | |
| 00840 | <1% | 62 | $244.60 | |
| 94761 | <1% | 412 | $226.46 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,394 | $216.23 |
| 72128 | <1% | 30 | $208.29 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 25 | $199.50 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 983 | $198.79 |
| J2704 | Injection, propofol, 10 mg | <1% | 4,277 | $186.49 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 178 | $184.46 |
| 80329 | <1% | 242 | $181.62 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,388 | $172.72 |
| 85007 | <1% | 34 | $167.77 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,053 | $167.13 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 492 | $149.17 |
| 82652 | <1% | 13 | $148.60 | |
| 94760 | <1% | 3,510 | $137.86 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 431 | $135.98 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 964 | $129.69 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,920 | $117.75 |
| 84481 | <1% | 12 | $110.84 | |
| 83721 | <1% | 12 | $106.64 | |
| G0404 | Electrocardiogram, routine ecg with 12 leads; tracing only, without interpretation and report, performed as a screening for the initial preventive physical examination | <1% | 61 | $103.63 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 793 | $100.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 990 | $95.63 |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 342 | $86.84 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,561 | $78.23 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,759 | $70.03 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 110 | $68.58 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 13 | $63.06 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 103 | $60.57 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,310 | $57.30 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 248 | $53.56 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 355 | $53.36 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 298 | $51.49 |
| 82150 | <1% | 30 | $35.82 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 523 | $35.21 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 108 | $34.56 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 87 | $34.50 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 158 | $34.43 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 271 | $33.92 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 649 | $29.69 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 676 | $28.32 |
| 81002 | <1% | 541 | $27.97 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 142 | $27.46 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 111 | $25.96 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 331 | $20.97 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 217 | $16.95 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 335 | $14.92 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 299 | $13.64 |
| A4217 | Sterile water/saline, 500 ml | <1% | 67 | $13.36 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 324 | $12.57 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 32 | $10.25 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 16 | $8.22 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 95 | $7.42 |
| J7999 | Compounded drug, not otherwise classified | <1% | 52 | $5.22 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 95 | $4.57 |
| J1815 | Injection, insulin, per 5 units | <1% | 56 | $4.28 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 441 | $3.83 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 34 | $2.33 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 118 | $1.68 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 43 | $1.17 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 44 | $0.87 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 38 | $0.72 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 246 | $0.52 |
| A9270 | Non-covered item or service | <1% | 8,696 | $0.39 |
| 88312 | 0% | 12 | $0.00 | |
| A4649 | Surgical supply; miscellaneous | 0% | 15 | $0.00 |
| 00811 | 0% | 332 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 79 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 238 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 29 | $0.00 |
| 0753T | 0% | 111 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 57 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 46 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 55 | $0.00 |
| 01810 | 0% | 17 | $0.00 | |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 0% | 13 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 135 | $0.00 |
| 76377 | 0% | 248 | $0.00 | |
| 00813 | 0% | 208 | $0.00 | |
| C1769 | Guide wire | 0% | 219 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 27 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 38 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 13 | $0.00 |
| 82803 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.